Docetaxel/Carboplatin

Phase 3Small molecule

SShanghai Jiao Tong University School of Medicine

Docetaxel/Carboplatin is one of 63 small molecule programs targeting Nasopharyngeal Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nasopharyngeal CarcinomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Nasopharyngeal CarcinomaPhase 3

Active, not recruiting

Non-Small Cell Lung CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Docetaxel/Carboplatin

SShanghai Jiao Tong University School of Medicine

Phase 3

1 2

PORTRAZZA

Eli Lilly

Preclinical

8 3

Lenvima

Eisai

Preclinical

6 4

Vizimpro

Pfizer

Preclinical

4 5

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 6

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—7

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Treatment

1 9

Vidaza

Bristol-Myers Squibb

Preclinical

1 10

Immune Checkpoint Inhibitor

IImmuneSensor Therapeutics Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Nasopharyngeal Carcinoma

NCT03919552

Q4 2027

Phase 1Recruiting

Non-Small Cell Lung Cancer

NCT02889666

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer

Recruiting·SShanghai Jiao Tong University School of Medicine·Phase 1·NCT02889666·500 enrolled

Chemotherapy1 trial

Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00621049·112 enrolled

Nasopharyngeal Carcinoma1 trial

Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma

Recruiting·NNanfang Hospital, Southern Medical University·Phase 3·NCT03919552·482 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Docetaxel/Carboplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Docetaxel/Carboplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Docetaxel/Carboplatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Jiao Tong University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SShanghai Jiao Tong University School of Medicine

Docetaxel/Carboplatin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Chemotherapy1 trial

Nasopharyngeal Carcinoma1 trial

References

Drug Info

Quick Facts

Related News